An observational study in Neurocognitive Disorder, Mild Cognitive Impairment and Alzheimer Dementia, sponsored by The University of Hong Kong. Status unknown at 1 site in Hong Kong. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-09-07.
Sponsored by The University of Hong Kong · Observational
The HKU Neurocognitive Disorder (NCD) Cohort is a hospital-based, prospective, observational study of older HK Chinese adults with cognitive impairment, with a special focus on studying patients with subjective cognitive decline and mild cognitive impairment.
The HKU Neurocognitive Disorder (NCD) Cohort is a hospital-based, prospective, observational study of older HK Chinese adults with cognitive impairment, with a special focus on studying patients with subjective cognitive decline and mild cognitive impairment, and in particular the biomarkers that predict cognitive and functional decline.
Comprehensive profiling of each subject is performed through a multi-domain assessment protocol including detailed demographics, lifestyle factors, neuropsychological battery, mood, MRI, genetics, blood biomarkers, and other patient-centred parameters including level of disability, quality of life and societal engagement. Ongoing annual follow up captures the essential clinical events and changes in neurocognitive function (conversion to MCI or dementia), mood, level of disability and quality of life; as well as repeat blood tests.
The HKU NCD Cohort is the first-ever Asian dementia cohort to be formally included into the Dementia Platforms UK, achieving an international collaborative status with other UK-based cohorts. The study neuropsychological battery is aligned with the NACC UDS3 battery.
274 studies on the registry are indexed under Neurocognitive Disorders; 90 are open to participants now.
This study's planned enrollment of 500 is above the median of 150 across 96 observational studies indexed under Neurocognitive Disorders.
Browse Neurocognitive Disorders studies →The University of Hong Kong is the lead sponsor of 1,292 studies on the registry; 348 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Older adults with or without neurocognitive disoder. HKU NCD Cohort focuses primarily on people with Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
No subjective memory complaints Normal HK-MoCA Normal instrumental ADL All interventions as described
Diagnostic Test: Neurocognitive battery · Diagnostic Test: MRI · Biological: Blood tests · Diagnostic Test: EEG with event-related potential (ERP)
Subjective memory complaints Normal HK-MoCA Normal instrumental ADL All interventions as described
Diagnostic Test: Neurocognitive battery · Diagnostic Test: MRI · Biological: Blood tests · Diagnostic Test: EEG with event-related potential (ERP) · Diagnostic Test: Amyloid PET CT
Subjective memory complaints Low HK-MoCA Normal instrumental ADL All interventions as described
Diagnostic Test: Neurocognitive battery · Diagnostic Test: MRI · Biological: Blood tests · Diagnostic Test: EEG with event-related potential (ERP) · Diagnostic Test: Amyloid PET CT
Subjective memory complaints Low HK-MoCA Poor instrumental ADL Probable Alzheimer's disease All interventions as described except EEG with ERP
Diagnostic Test: Neurocognitive battery · Diagnostic Test: MRI · Biological: Blood tests · Diagnostic Test: Amyloid PET CT
Subjective memory complaints Low HK-MoCA Poor instrumental ADL Related to stroke / cerebrovascular disease All interventions as described except EEG with ERP
Diagnostic Test: Neurocognitive battery · Diagnostic Test: MRI · Biological: Blood tests · Diagnostic Test: Amyloid PET CT
Cognitive impairment status (SCD, MCI, dementia), HK-MoCA, Clinical Dementia Rating (CDR sum of squares), Geriatric Depression Scale (GDS-15), Neuropsychiatric Index (NPI), Barthel Index, Lawton's IADL, Life-Space Assessment, Mini-Nutrition Assessment (MNA), Quality of Life for Alzheimer's Disease (QoL-AD, patient and carer parts), frailty status (FRAIL scale), handgrip strength, walking speed, exercise status, sleep quality, Charlson comorbidity index (CCI, age-adjusted). NACC: Story recall, Benson's complex figure copy, colour trail test (black \& white), verbal fluency, digit forward and backward span.
MRI: T1, T2, FLAIR, SWI, DTI, fMRI, ASL, MRS, for selected patients
Stored samples (unanalysed): serum, plasma, buffy coat (PBMC); also processed for microvesicles and exosome analysis
128-channel EEG with ERP for Go/NoGo and Prospective Memory (PM) tasks for selected patients
F18 Flutametamol PET CT for selected patients
Cognitive decline
Change in total HK-MoCA score between baseline and follow-up
Time frame: 1 year
Functional decline
Change in Lawton's IADL score between baseline and follow-up
Time frame: 1 year
Neuropsychiatric decline
Change in Neuropsychiatric Index (NPI) between baseline and follow-up
Time frame: 1 year
Quality of life decline
Change in QoL-AD score between baseline and follow-up
Time frame: 1 year
Change in cognitive impairment status
Progression to mild cognitive impairment (MCI) or dementia status
Time frame: 1 year
Plan to share: Yes — Share with Dementias Platform UK (www.dementiasplatform.uk)
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Due to be shared from 2017, indefinitely.
Access criteria: Via Dementias Platform UK (www.dementiasplatform.uk)
Data sharing details ↗ · www.dementiasplatform.uk
Started Sep 2014 (actual). Primary completion is estimated for Jan 2022, 88 months after the start.
Of 52 non-industry observational studies under Neurocognitive Disorders, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 78. This study's planned 88 months is above that.
Counting every sponsor, half of 53 studies reached it within 44 months; a quarter within 20 and three quarters within 78.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.